Bladder Clinical Trials

MEDI-4736-1108

A Phase I, open-label, multi-center study to evaluate the safety, tolerability and pharmacokinetics of MEDI4736 in patients with advanced solid tumors. Click here to learn more.

D4190C00010 

A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors. Click here to learn more.

 

 

 

 

 

 

 

 

 

 

 

 

 

UCBC